Safiglipron: A New Oral Pill for Type 2 Diabetes

Last Updated on 10/11/2026 by DrHelal, MD
Medical Doctor with 50+ Years of Clinical Practice • [Read Full Author Bio & Credentials →]

A new medicine called safiglipron is now being studied for Type 2 Diabetes, and early results are very encouraging. If you live with type 2 diabetes, you know how important to find medicine that works well and is easy to take. Every day, patients, at Helal Medical Manila, ask me about new options to control their blood sugar and without too many rules or side effects.

In this article I will explore what is Safiglipron, what this study was about and what did they find. I will also mention some important note to consider!

About Safiglipron: A New Oral Pill for Type 2 Diabetes

This medicine works like a natural body hormone; it helps control blood sugar levels (Type 2 Diabetes), after meals and between meals too. Unlike some similar treatments, you can take it with or without food and you do not need to fast or avoid certain meals. This makes it much easier to fit into your daily life.

Researchers compared it directly to a medicine many people already use, called dapagliflozin. The main goal of the study was to see how well each medicine lowered HbA1c, the number that shows your average blood sugar over 2-3 months.

What was this study about?

Researchers tested this safiglipron, a once-daily pill that can help control blood sugar, against a commonly used diabetes pill called dapagliflozin. Safiglipron proved to be different than other treatments; it is taken without needing to fast or avoid certain foods.

The trial included 810 adults with type 2 diabetes whose blood sugar was not well controlled by metformin alone. People were split into four groups:

• Safiglipron 30 mg daily
• Safiglipron 60 mg daily
• Safiglipron 90 mg daily
• Dapagliflozin 10 mg daily

The main goal was to see how well each medicine lowered HbA1c.

What did they find?

1. Blood sugar control

• All three doses of safiglipron worked at least as well as dapagliflozin at lowering HbA1c after 32 weeks.
• The highest dose — 90 mg — actually worked better than dapagliflozin.
• More people reached their target blood sugar levels on safiglipron:
  • HbA1c below 7%: 55–64% on safiglipron vs. 37% on dapagliflozin
  • HbA1c at or below 6.5%: 39–49% on safiglipron vs. 16% on dapagliflozin

2. Weight loss and other Benefits

Weight Loss and Extra BenefitsWeight change was another important part of the study. The highest dose—90 mg—helped people lose an average of 4.2 percent of their body weight. The 60 mg dose and dapagliflozin both gave about 3.6 percent loss. The lowest dose—30 mg—produced 2.4 percent loss. This is useful because it gives you options: if you need to lose weight, higher doses help; if your weight is already healthy, the lower dose supports sugar control without too much drop.Safiglipron works in a different way than dapagliflozin. It helps your pancreas make insulin when you need it, while dapagliflozin helps your body use insulin more efficiently. Because they work differently, doctors may one day prescribe them together for even better results. Safiglipron also lowered blood pressure and showed early signs of protecting kidney health—two major concerns for people with diabetes.

3. Safety and side effects

No medicine is perfect for everyone, so knowing what to watch for is important. The most common side effects with safiglipron were nausea, upset stomach, or diarrhea. These were mostly mild and tended to improve after a few weeks as the body adjusted. About 4 percent of people stopped taking it due to side effects, compared to 1.5 percent on dapagliflozin. This is something to keep in mind but should not overshadow the benefits.

Importantly, no serious low blood sugar reactions happened in any group. This means safiglipron is less likely to cause dangerous sugar drops that can make you dizzy, confused, or even faint. No liver safety concerns were found either. These are very positive signs, especially since people with diabetes often take medicine for many years and need options that stay safe over time.

What does this mean for you?

• Safiglipron is an effective once-daily pill for type 2 diabetes that you can take with or without food — no fasting required.
• All three doses controlled blood sugar well. The 90 mg dose gave the strongest control.
• It works differently than dapagliflozin, so they could be used together in the future for even better results.
• Side effects are mostly stomach-related and usually improve as your body gets used to the medicine.

Important notes

🔹 Not yet approved or available — it is being researched and not yet available by prescription.
🔹 Study done in China — results may vary in other groups
🔹 Longer studies needed to confirm long‑term heart & kidney benefits

What to do now: Keep taking your medicine exactly as prescribed. Ask your doctor about safiglipron at your next visit — it may become a great new option soon

Published online October 5, 2026 in Nature Medicine: Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 …

Summary

Safiglipron is a promising new once-daily pill for type 2 diabetes. It controls blood sugar well—sometimes better than existing options—and you can take it with or without food. Higher doses give stronger sugar control and weight loss; the lower dose works gently for those who do not need or want weight loss. Side effects are mostly mild stomach discomfort that improves with time.

It works differently than other diabetes medicines, so it may be used together with them in the future for even better results. It also lowered blood pressure and showed early signs of protecting kidneys. No serious low blood sugar or liver problems appeared in this study, which is reassuring. Approval is still pending, and longer trials are ongoing.

For now, keep working closely with your doctor. Good diabetes care combines medicine, healthy eating, regular movement, and consistent check-ups. When safiglipron becomes available, it will be another powerful tool to help you live a longer, healthier life. Your doctor will guide you if and when it is right for your care plan.

References

1. Study Source — Oral GLP-1 Safiglipron Cuts HbA1c in OUTSTAND-1 Trial
2. World Health Organization — Diabetes Treatment Guidelines Management of Diabetes – World Health Organization
3. Type 2 Diabetes – NIDDK – National Institute of Diabetes and Digestive …
4. National Institute of Diabetes and Digestive and Kidney Diseases …